TrialAnnals of the rheumatic diseases2012

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.

Susan Manzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.